Sun Pharmaceutical Industries Limited (SUNPHARMA.BO)
INR 1688.75
(1.22%)
INR 1688.75
(1.22%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 13.3 Million INR | -99.76% |
| 2022 | 5.63 Billion INR | 17.02% |
| 2021 | 4.81 Billion INR | -46.37% |
| 2020 | 8.98 Billion INR | -55.73% |
| 2019 | 20.28 Billion INR | 33.25% |
| 2018 | 15.22 Billion INR | -14.08% |
| 2017 | 17.72 Billion INR | 23.4% |
| 2016 | 14.36 Billion INR | -53.83% |
| 2015 | 31.1 Billion INR | 128.74% |
| 2014 | 13.59 Billion INR | 2693.86% |
| 2013 | 486.7 Million INR | -57.77% |
| 2012 | 1.15 Billion INR | -25.84% |
| 2011 | 1.55 Billion INR | -1.18% |
| 2010 | 1.57 Billion INR | -8.1% |
| 2009 | 1.71 Billion INR | -4.33% |
| 2008 | 1.78 Billion INR | 24.55% |
| 2007 | 1.43 Billion INR | -87.11% |
| 2006 | 11.14 Billion INR | -40.55% |
| 2005 | 18.74 Billion INR | 2.83% |
| 2004 | 18.23 Billion INR | 341.37% |
| 2003 | 4.13 Billion INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2024 Q2 | 13.3 Million INR | 0.0% |
| 2023 Q2 | 3.13 Billion INR | 0.0% |
| 2023 Q4 | 13.3 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 13.3 Million INR | -99.76% |
| 2023 Q1 | - INR | -100.0% |
| 2022 FY | 5.63 Billion INR | 17.02% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 4.47 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q4 | 5.63 Billion INR | 0.0% |
| 2021 Q4 | 4.81 Billion INR | 0.0% |
| 2021 FY | 4.81 Billion INR | -46.37% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 6.48 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 FY | 8.98 Billion INR | -55.73% |
| 2020 Q4 | 8.98 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 17.6 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 20.28 Billion INR | 33.25% |
| 2019 Q4 | 20.28 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 21.35 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 15.22 Billion INR | -14.08% |
| 2018 Q4 | 15.22 Billion INR | 0.0% |
| 2018 Q2 | 13.77 Billion INR | 0.0% |
| 2017 FY | 17.72 Billion INR | 23.4% |
| 2017 Q4 | 17.72 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 16.99 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q4 | 14.36 Billion INR | 0.0% |
| 2016 FY | 14.36 Billion INR | -53.83% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q2 | 18.59 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 22.34 Billion INR | 0.0% |
| 2015 Q4 | 31.1 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 31.1 Billion INR | 128.74% |
| 2014 Q4 | 13.59 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 2.16 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 13.59 Billion INR | 2693.86% |
| 2013 FY | 486.7 Million INR | -57.77% |
| 2013 Q4 | 486.7 Million INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 1.3 Billion INR | 0.0% |
| 2012 FY | 1.15 Billion INR | -25.84% |
| 2012 Q4 | 1.15 Billion INR | 0.0% |
| 2012 Q2 | 1.57 Billion INR | 0.0% |
| 2011 Q4 | 1.55 Billion INR | 0.0% |
| 2011 FY | 1.55 Billion INR | -1.18% |
| 2010 FY | 1.57 Billion INR | -8.1% |
| 2009 FY | 1.71 Billion INR | -4.33% |
| 2008 FY | 1.78 Billion INR | 24.55% |
| 2007 FY | 1.43 Billion INR | -87.11% |
| 2006 FY | 11.14 Billion INR | -40.55% |
| 2005 FY | 18.74 Billion INR | 2.83% |
| 2004 FY | 18.23 Billion INR | 341.37% |
| 2003 FY | 4.13 Billion INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 628.8 Million INR | 97.885% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 99.938% |
| Glenmark Life Sciences Limited | 147.61 Million INR | 90.99% |
| Granules India Limited | 689.71 Million INR | 98.072% |
| Indoco Remedies Limited | 3.51 Billion INR | 99.622% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 235.2 Million INR | 94.345% |
| Alkem Laboratories Limited | 400 Million INR | 96.675% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Brooks Laboratories Limited | 3.56 Million INR | -273.072% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | 52.22% |
| Bajaj HealthCare Limited | 650.34 Million INR | 97.955% |
| Bliss GVS Pharma Limited | 355.92 Million INR | 96.263% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 99.778% |
| Eris Lifesciences Limited | 6.54 Billion INR | 99.797% |
| FDC Limited | 2.46 Million INR | -439.335% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 99.123% |
| Gufic Biosciences Limited | 1.53 Billion INR | 99.136% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | 88.085% |
| Ipca Laboratories Limited | 5.8 Billion INR | 99.771% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | 82.4% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 99.275% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Laurus Labs Limited | 8.6 Billion INR | 99.845% |
| Lupin Limited | 1.55 Billion INR | 99.143% |
| Mankind Pharma Limited | 248.67 Million INR | 94.652% |
| Medicamen Biotech Limited | 12.55 Million INR | -5.934% |
| Medico Remedies Limited | 8.67 Million INR | -53.367% |
| Megasoft Limited | 1.35 Billion INR | 99.02% |
| NATCO Pharma Limited | 53 Million INR | 74.906% |
| Piramal Pharma Limited | 24.83 Billion INR | 99.946% |
| RPG Life Sciences Limited | -30.3 Million INR | 143.894% |
| Sigachi Industries Limited | 265.79 Million INR | 94.996% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | 93.737% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 1191.058% |
| Unichem Laboratories Limited | 382.22 Million INR | 96.52% |
| Wanbury Limited | 820 Million INR | 98.378% |
| Windlas Biotech Limited | 20.18 Million INR | 34.093% |
| ZIM Laboratories Limited | 356 Million INR | 96.264% |
| Zydus Lifesciences Limited | 251 Million INR | 94.701% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | 87.523% |
| Divi's Laboratories Limited | 20 Million INR | 33.5% |
| Hester Biosciences Limited | 1.81 Billion INR | 99.268% |
| Procter & Gamble Health Limited | 68.8 Million INR | 80.669% |
| Amrutanjan Health Care Limited | 13.96 Million INR | 4.782% |
| Bal Pharma Limited | 363.82 Million INR | 96.344% |
| Strides Pharma Science Limited | 6.71 Billion INR | 99.802% |
| Venus Remedies Limited | 386.8 Million INR | 96.562% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -3225.0% |
| Nectar Lifesciences Limited | 1.4 Billion INR | 99.052% |
| Shilpa Medicare Limited | 5.6 Billion INR | 99.763% |
| Aarti Drugs Limited | 2.75 Billion INR | 99.517% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Ind-Swift Limited | 10.09 Billion INR | 99.868% |
| Valiant Laboratories Limited | 746.63 Million INR | 98.219% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | 94.374% |
| Solara Active Pharma Sciences Limited | 1.05 Billion INR | 98.743% |
| Themis Medicare Limited | 267.74 Million INR | 95.032% |
| Hikal Limited | 4.22 Billion INR | 99.685% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 99.917% |
| Sequent Scientific Limited | 1.42 Billion INR | 99.068% |
| Novartis India Limited | 50.7 Million INR | 73.767% |
| Wockhardt Limited | 8.91 Billion INR | 99.851% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 99.958% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Neuland Laboratories Limited | 449.2 Million INR | 97.039% |
| Morepen Laboratories Limited | 33.64 Million INR | 60.464% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | 90.041% |